In a regulatory filing, Biogen disclosed that on May 3, the European Commission notified the company of its decision that the period of regulatory market protection for Tecfidera extends until February 2, 2025. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen slips after competitor Eli Lilly’s Alzheimer’s trial hits target
- Lilly’s Gain Is Biogen’s Pain After Promising Alzheimer’s Data
- Biogen price target raised to $340 from $315 at Mizuho
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Biogen upgraded to Buy at Guggenheim on potential for growth
